LBC Tank Terminals Signs Agreement with MEGlobal Americas, Inc. to Construct a New Terminal in Freeport, Texas
LBC is pleased to announce that agreements have been finalized with MEGlobal Americas, Inc. for the design, engineering, construction, and operation of a new terminal. This terminal will be constructed adjacent to MEGlobal’s world-scale monoethylene glycol (MEG) manufacturing plant and connected by pipeline. The terminal will be located on property owned by MEGlobal Americas and leased to LBC Freeport Terminal LLC. The process plant is to be constructed 60 miles south of Houston at MEGlobal’s new Oyster Creek site in Freeport, Texas.
LBC Freeport will be an integrated part of MEGlobal’s Supply Chain, secured through a long-term contract and pipeline connection. The main products to be handled are monoethylene glycol and diethylene glycol. Upon receipt of the necessary regulatory permits the construction commenced in August 2017 and the terminal is planned to be operational during 2019.
“We are delighted to enter into this agreement and partner with MEGlobal Americas on this project. With over 30 years of historical experience in handling Glycols, this project opportunity fits our portfolio and investment risk models and is aligned with our business strategy to further optimize, build-out and expand our business. This project very much fits our expertise in constructing, managing and operating chemical terminals and we look forward to a successful business partnership with MEGlobal.,” stated by John Grimes, Regional Business President Americas.
MEGlobal – an EQUATE company is a world leader in the manufacture, supply and marketing of monoethylene glycol (MEG) and diethylene glycol (DEG), collectively known as ethylene glycol (EG). MEGlobal serves customers around the world, and has production facilities in Fort Saskatchewan and Prentiss, Alberta, Canada. EG is a key raw material used in a wide variety of products and applications including the manufacture of polyester fibers, polyethylene terephthalate resins (PET), antifreeze formulations and other industrial products. MEGlobal embraces the principles of Responsible Care, ensuring that our employees, neighbors, communities and the environment are protected at all times. For more information, visit www.MEGlobal.biz.
LBC Tank Terminals owns and operates a global network of terminals at key locations in the United States, Europe and China. We are a top-tier global independent operator of bulk liquid storage facilities for petrochemicals, petroleum products and base oil products and offers loading / unloading services for all modes of transportation. Underlying the entire ethos of the company is our focus on corporate and social governance in which we strive to have a positive effect upon society and ensure that there is no such thing as a dangerous product, at least not when under our care.
LBC Belgium Holding NV
Christina Schosser, +32 (0)15 28 73 10
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc20.11.2018 17:33 | Tiedote
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”). The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights. The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition. SHP647 is an exciting pipeline compound
ResMed Elects Harjit Gill to Its Board of Directors20.11.2018 17:05 | Tiedote
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005179/en/ Harjit Gill, BA (Photo: Business Wire) Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed’s board after serving on it since July 1994. Ms. Gill’s appointment and Dr. Pace’s retirement both took effect Thursday, November 15. Ms. Gill has more than 25 years’ experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Phi
PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum20.11.2018 15:12 | Tiedote
PTC (NASDAQ: PTC) today announced that it has acquired Frustum Inc., an advanced generative design software company, for approximately $70 million. Frustum’s technology for generative design—an approach that leverages artificial intelligence (AI) to generate design options—is a transformative addition to the PTC Creo portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005326/en/ PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum (Graphic: Business Wire) Based in Boulder, Colorado, Frustum offers patented desktop and cloud-based engineering software that enables designers and engineers to go beyond the limits of their personal experience by leveraging powerful AI capabilities that guide the discovery of high-performance, next-generation product designs. “PTC is pushing the boundaries of innovation with this acquisition,” said Jim
United First Partners Launches UFP Fintech20.11.2018 15:00 | Tiedote
United First Partners (“UFP”), a leading independent Research, Brokerage, Advisory & Investment group is pleased to announce the launch of its latest venture: UFP Fintech. UFP Fintech invests in early stage Fintech, Proptech and Legaltech startups. Under the leadership of the entity’s CIO Christophe Petetin, a veteran investor in the Fintech space with an unparalleled investment track record in Fintech start-ups, UFP Fintech aims to become a global leader in Early Stage Fintech Investments. In recent years, Christophe and the UFP Fintech team have seeded a major unicorn and several other market leading entities. Christophe is a premier Fintech thought leader, who also acts in an advisory capacity to governmental and regulatory bodies, such as the FCA and ISO 20022 to create the next generation of standards for Fintech, payments, data, securities & digital currencies. Christophe commented “The financial industry is getting rebuilt from the ground up creating unprecedented opportunities.
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases20.11.2018 14:00 | Tiedote
Danish dermatology specialists LEO Pharma and California rare disease pioneers PellePharm today announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005227/en/ “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin diseases. Supporting our ambitious 2025 strategy, it marks LEO Pharma’s entrance in rare skin diseases and it offers a unique opportunity to bring the first treatment forward to people suffering from a very severe skin disease for which there currently are no approved therapies,” sai
IDEMIA Provides SK Telecom in South Korea with GMSA Compliant Smart Connect Solution to Activate and Manage eSIM Device Lifecycles20.11.2018 12:00 | Tiedote
IDEMIA, the global leader in Augmented Identity, is proud to have been selected by SK Telecom, the number one telecommunication operator in South Korea, to launch the first eSIM Connected watch based on GSMA Consumer standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005231/en/ Crédits : IDEMIA As a leading actor in the telecom field, IDEMIA is at the forefront of the digital revolution and is committed to bringing protected and convenient experiences to mobile operator customers. Leveraging its industrial leadership and appetite for innovation, IDEMIA will be providing SK Telecom its GSMA compliant solution. Based on IDEMIA’s Smart Connect Subscription management solution also known as remote SIM provisioning, the technology remotely connects the eSIM of the smart watch to the SK Telecom’s network without inserting a physical SIM card. This technology is also compliant with the latest GSMA standards ensuring in
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme